Nureddin Almaddah, MD
Interventional Cardiology · Little Rock, ARNPI 1467891705
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.4%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Abbott at 33.1% of the total. Reporting peaked in 2022 at $3,368 and has fallen 91.1% since, to $301 in 2025.
Across 97 payments — averaging $103.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$3K
- Shockwave Medical, Inc$1K
- Penumbra, Inc.$662
- Asahi Intecc USA, Inc.$479
- Abiomed$414
- plus $1K from 16 others
What the payments were for
- Travel & lodging$4,52545%
- Food & beverage$5,36553%
- Entertainment$1501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 28 | $3,327 |
| Boston Scientific | 7 | $2,539 |
| Shockwave Medical, Inc | 15 | $1,354 |
| Penumbra, Inc. | 5 | $662 |
| Asahi Intecc USA, Inc. | 19 | $479 |
| Abiomed | 4 | $414 |
| Inari Medical, Inc. | 1 | $218 |
| Livanova USA, Inc. | 2 | $165 |
| GE HealthCare | 1 | $161 |
| Medtronic | 1 | $152 |
| Shimadzu Precision Instruments, Inc. | 1 | $150 |
| Avinger Inc. | 1 | $105 |
| United Therapeutics Corporation | 1 | $84 |
| Cardiovascular Systems Inc. | 1 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| AstraZeneca | 1 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $22 |
| BD | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CROSSBOSS$2,539
- OMNILINK ELITE$1,674
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,128
- Indigo System$486
- Dragonfly OCT$445
- Impella$278
- FLOWTRIEVER CATHETER, S$218
- CT THROMBECTOMY SYSTEM KIT$218
- CoreValve Evolut$152
- TRINIAS$150
- TandemHeart$143
- Confirm Rx$122
- ASAHI PTCA Guide Wire$121
- XIENCE SIERRA$120
- PANTHERIS$105
How this compares
$10,040 in reported general payments places this provider in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 296 | $244,807 |
| EntrestoSacubitril/Valsartan | 128 | $128,971 |
| CamzyosMavacamten | 12 | $96,341 |
| FarxigaDapagliflozin Propanediol | 64 | $52,537 |
| Repatha SureclickEvolocumab | 61 | $45,730 |
| XareltoRivaroxaban | 28 | $31,719 |
| BrilintaTicagrelor | 43 | $24,336 |
| CorlanorIvabradine Hcl | 15 | $13,962 |
| MultaqDronedarone Hcl | 13 | $11,707 |
| ClopidogrelClopidogrel Bisulfate | 796 | $7,969 |
| Prasugrel Hcl | 51 | $3,834 |
| Metoprolol Succinate | 312 | $3,717 |
| Valsartan | 134 | $3,601 |
| Carvedilol | 471 | $3,395 |
| Spironolactone | 363 | $3,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $244,807296 claims |
| NovartisEntresto | $18 | $128,971128 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $31 | $96,34112 claims |
| AstraZenecaFarxiga, Brilinta | $24 | $76,872107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Little Rock
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Stephen BroughtonLittle Rock$34K
- Mahesh Anantha NarayananLittle Rock$26K
- Aravind RaoLittle Rock$17K
- Patrick TobbiaLittle Rock$14K
- Subhi AlarefLittle Rock$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.